MedPage Today) -- There may be a future for cardiac myosin inhibitors in heart failure with preserved ejection fraction (HFpEF), according to the proof-of-concept EMBARK-HFpEF trial. An established cardiac myosin inhibitor for hypertrophic cardiomyopathy...
Copyright © 2024 fu.ci. All Rights Reserved